KALV — KalVista Pharmaceuticals, Inc. stock price, charts and financials
QT68KalVista Pharmaceuticals, Inc.KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
27.00
+0.00%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -4.28 | Insider Own | 13.27% | Shs Outstand | 53.24M | Perf Week | 0.19% |
| Market Cap | 1.44B | Forward P/E | 42.19 | EPS next Y | 0.64 | Insider Trans | -4.74% | Shs Float | 38.18M | Perf Month | 0.75% |
| Enterprise Value | 1.42B | PEG | - | EPS next Q | -0.29 | Inst Own | - | Short Float | - | Perf Quarter | 59.39% |
| Income | -189.00M | P/S | 12.39 | EPS this Y | 71.70% | Inst Trans | - | Short Ratio | - | Perf Half Y | 60.14% |
| Sales | 116.00M | P/B | - | EPS next Y | 152.84% | ROA | -41.28% | Short Interest | - | Perf YTD | 67.18% |
| Book/sh | -0.06 | P/C | 4.79 | EPS next 5Y | - | ROE | -1057.44% | 52W High | 27.00 0.00% | Perf Year | 100.59% |
| Cash/sh | 5.63 | P/FCF | - | EPS past 3/5Y | - | ROIC | -46.81% | 52W Low | 9.83 174.67% | Perf 3Y | 173.28% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 92.03% | Volatility | 0.04% 0.15% | Perf 5Y | -3.85% |
| Dividend TTM | - | EV/Sales | 12.25 | EPS Y/Y TTM | -15.99% | Oper. Margin | -120.80% | ATR (14) | 0.20 | Perf 10Y | 39.75% |
| Dividend Ex-Date | - | Quick Ratio | 5.52 | Sales Y/Y TTM | - | Profit Margin | -119.44% | RSI (14) | 75.89 | Recom | 2.15 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.58 | EPS Q/Q | -18.68% | SMA20 | 0.45% | Beta | -0.10 | Target Price | 27.00 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | - | SMA50 | 11.14% | Rel Volume | 0.00 | Prev Close | 27.00 |
| Employees | 275 | LT Debt/Eq | -50.00 | Earnings | Aug 13 | SMA200 | 58.99% | Avg Volume | 3.45M | Price | 27.00 |
| IPO Date | Apr 09, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -60.66% 21.26% | Net Debt/EBITDA | -0.47 | Volume | 0 | Change | 0.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-01-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $37 → $27 |
| Apr-30-26 | Downgrade | Needham | Buy → Hold | |
| Apr-29-26 | Reiterated | Leerink Partners | Outperform | $20 → $27 |
| Jan-09-26 | Reiterated | HC Wainwright & Co. | Buy | $20 → $37 |
| Jan-06-26 | Reiterated | Needham | Buy | $28 → $32 |
| Nov-11-25 | Reiterated | JMP Securities | Market Outperform | $29 → $28 |
| Nov-05-24 | Reiterated | Needham | Buy | $38 → $28 |
| Sep-06-24 | Reiterated | Leerink Partners | $20 | |
| Sep-06-24 | Reiterated | HC Wainwright & Co. | Buy | $20 |
| Jul-08-22 | Reiterated | Needham | Buy | $38 |
Company
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2026 12/31/2025 | FY 2025 4/30/2025 | FY 2024 4/30/2024 | FY 2023 4/30/2023 | FY 2022 4/30/2022 | FY 2021 4/30/2021 | FY 2020 4/30/2020 | FY 2019 4/30/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 116 | 74 | 0 | 0 | 0 | 0 | 0 | 13 | 16 | |
| Cost of Goods Sold Incl. D&A | 25 | 6 | 0 | 86 | 0 | 0 | 41 | 40 | 0 | |
| Gross Profit | 90 | 68 | 0 | -86 | 0 | 0 | -41 | -28 | 16 | |
| Selling, General and Administrative Excl. Other | 238 | 184 | 116 | 54 | 31 | 26 | 17 | 13 | 11 | |
| Research and Development | 64 | 56 | 72 | 86 | 80 | 70 | 41 | 40 | 35 | |
| Other Operating Expense | -16 | -1 | 0 | -86 | 0 | 1 | -41 | -40 | 0 | |
| Operating Income | -195 | -172 | -188 | -140 | -111 | -97 | -58 | -41 | -30 | |
| Interest Expense | 27 | 19 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 27 | 20 | 14 | 5 | 18 | 14 | 12 | 12 | 9 | |
| Net Income Before Taxes | -193 | -171 | -180 | -135 | -93 | -82 | -46 | -29 | -21 | |
| Income Taxes | -4 | -7 | 3 | -8 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -189 | -164 | -183 | -127 | -93 | -82 | -46 | -29 | -21 | |
| Net Income From Continuing Operations | -189 | -164 | -183 | -127 | -93 | -82 | -46 | -29 | -21 | |
| Net Income | -189 | -164 | -183 | -127 | -93 | -82 | -46 | -29 | -21 | |
| EPS (Recurring) | -4.28 | -3.23 | -3.69 | -3.44 | -3.33 | -3.36 | -2.33 | -1.64 | -1.38 | |
| EPS (Basic, Before Extraordinaries) | -4.28 | -3.23 | -3.69 | -3.44 | -3.33 | -3.36 | -2.33 | -1.64 | -1.38 | |
| EPS (Diluted) | -4.28 | -3.23 | -3.69 | -3.44 | -3.33 | -3.36 | -2.33 | -1.64 | -1.38 | |
| EBITDA | -167 | -151 | -173 | -134 | -94 | -81 | -57 | -40 | -29 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 11.87 | 11.13 | — | — | — | — | — | 15.11 | 21.56 | |
| Gross Margin | 77.59 | 91.89 | — | — | — | — | — | -215.38 | 100.00 | |
| Operating Margin | -168.10 | -232.43 | — | — | — | — | — | -315.38 | -187.50 | |
| Net Margin | -162.93 | -221.62 | — | — | — | — | — | -223.08 | -131.25 | |
| Shares Outstanding | 51 | 51 | 50 | 37 | 28 | 24 | 19 | 18 | 15 | |
| Market Capitalization | 1,377 | 824 | 689 | 420 | 239 | 306 | 474 | 196 | 345 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 27 '26 | Sale | 26.78 | 33,800 | 905,225 | 229,918 | May 29 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 27 '26 | Option Exercise | 7.07 | 33,800 | 238,966 | 263,718 | May 29 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 26 '26 | Sale | 26.78 | 2,239 | 59,955 | 150,260 | May 27 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 26 '26 | Sale | 26.78 | 1,966 | 52,645 | 229,918 | May 27 |
| Sweeny Nicole | Chief Commercial Officer | May 26 '26 | Sale | 26.78 | 1,489 | 39,872 | 59,291 | May 27 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 22 '26 | Option Exercise | 0.00 | 3,125 | 0 | 231,884 | May 27 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 22 '26 | Option Exercise | 0.00 | 5,000 | 0 | 152,499 | May 27 |
| Sweeny Nicole | Chief Commercial Officer | May 22 '26 | Option Exercise | 0.00 | 5,000 | 0 | 60,780 | May 27 |
| Sweeny Nicole | Chief Commercial Officer | May 22 '26 | Sale | 26.78 | 1,861 | 49,846 | 55,780 | May 26 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | May 22 '26 | Sale | 26.78 | 10,926 | 292,646 | 479,989 | May 26 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 22 '26 | Sale | 26.78 | 2,358 | 63,158 | 228,759 | May 26 |
| Piekos Brian | Chief Financial Officer | May 22 '26 | Sale | 26.78 | 1,489 | 39,882 | 21,661 | May 26 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 22 '26 | Sale | 26.78 | 2,685 | 71,916 | 147,499 | May 26 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | May 21 '26 | Option Exercise | 0.00 | 6,250 | 0 | 150,184 | May 26 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER | May 21 '26 | Option Exercise | 0.00 | 3,750 | 0 | 231,117 | May 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.